,50 Ongoing clinical trials, such as the PSMAddition trial (NCT04720157), which is testing the combination of AR signaling inhibitors with or without 177Lu-PSMA-617 in the metastatic hormone-sensitive prostate cancer setting, will provide valuable insights into the potential synergistic effects of these treatment approaches. Here, AR is linked to prostate carcinoma.